Zacks Research Comments on STERIS’s Q3 Earnings (NYSE:STE)

STERIS plc (NYSE:STE) – Zacks Research dropped their Q3 2025 EPS estimates for STERIS in a report released on Thursday, October 24th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.20 for the quarter, down from their prior forecast of $2.27. The consensus estimate for STERIS’s current full-year earnings is $9.06 per share. Zacks Research also issued estimates for STERIS’s Q1 2026 earnings at $2.03 EPS, Q3 2026 earnings at $2.30 EPS and Q1 2027 earnings at $2.23 EPS.

STERIS (NYSE:STE) last announced its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The business’s quarterly revenue was down .4% compared to the same quarter last year. During the same period last year, the company earned $2.00 EPS.

Several other equities research analysts have also recently commented on STE. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. KeyCorp upped their target price on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and an average price target of $253.00.

STERIS Price Performance

Shares of STE stock opened at $224.01 on Monday. The firm has a market cap of $22.09 billion, a price-to-earnings ratio of 55.59 and a beta of 0.84. STERIS has a 12 month low of $195.47 and a 12 month high of $248.24. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. The stock has a 50-day moving average price of $234.76 and a 200 day moving average price of $226.46.

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 20th. Shareholders of record on Thursday, September 5th were paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 1.02%. This is a boost from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. STERIS’s payout ratio is presently 56.58%.

Insiders Place Their Bets

In other news, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the transaction, the director now owns 582 shares in the company, valued at $139,493.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the sale, the director now directly owns 582 shares in the company, valued at $139,493.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. J.Safra Asset Management Corp grew its stake in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 53 shares in the last quarter. Central Pacific Bank Trust Division bought a new position in STERIS in the third quarter valued at $28,000. Quent Capital LLC increased its stake in STERIS by 112.7% in the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 71 shares during the last quarter. Headlands Technologies LLC bought a new stake in STERIS during the 1st quarter worth about $36,000. Finally, Versant Capital Management Inc boosted its stake in shares of STERIS by 2,262.5% during the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 181 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.